News – Page 26 – Global Reach Health

July 15, 2022

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2022/07/Zonisade-Approved-to-Treat-Seizures-480x360.jpg" class="scale-with-grid wp-post-image" alt="Zonisade Approved to Treat Seizures" decoding="async" />

Zonisade Approved to Treat Seizures

Zonisade Approved to Treat Seizures

July 15, 2022 – Zonisade^TM (zonisamide oral suspension) has received FDA approval to provide adjunctive therapy for the treatment of partial onset seizures in patients

July 14, 2022

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2022/07/Xalkori-Granted-New-Indication-to-Treat-Non-Cancerous-Tumors-480x360.jpg" class="scale-with-grid wp-post-image" alt="Xalkori Granted New Indication to Treat Non-Cancerous Tumors" decoding="async" />

Xalkori Granted New Indication to Treat Non-Cancerous Tumors

Xalkori Granted New Indication to Treat Non-Cancerous Tumors

July 14, 2022 – Pfizer’s Xalkori® (crizotinib) has received a new indication to treat unresectable, recurrent, or refractory ALK-positive inflammatory yofibroblastic

July 14, 2022

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2022/07/Diacomit-Approved-for-Broader-Age-Group-480x360.jpg" class="scale-with-grid wp-post-image" alt="Diacomit Approved for Broader Age Group" decoding="async" />

Diacomit Approved for Broader Age Group

Diacomit Approved for Broader Age Group

July 14, 2022 – Diacomit^® (stiripentol) is now indicated for use with clobazam to treat seizures associated with Dravet syndrome in patients at least six months of age and

July 13, 2022

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2022/07/FDA-Authorizes-Additional-COVID-19-Vaccine-480x360.jpg" class="scale-with-grid wp-post-image" alt="FDA Authorizes Additional COVID-19 Vaccine" decoding="async" />

FDA Authorizes Additional COVID-19 Vaccine

FDA Authorizes Additional COVID-19 Vaccine

July 13, 2022 – The FDA has granted emergency use authorization to Novavax’s COVID-19 vaccine for the prevention of COVID-19 caused by the SARS-CoV-2 virus in adults.

July 8, 2022

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2022/07/Krystexxa-Approved-for-Use-with-Methotrexate-480x360.jpg" class="scale-with-grid wp-post-image" alt="Krystexxa Approved for Use with Methotrexate" decoding="async" />

Krystexxa Approved for Use with Methotrexate

Krystexxa Approved for Use with Methotrexate

July 8, 2022 – Krystexxa^® (pegloticase – Horizon Therapeutics) has received an expanded indication for co-administration with methotrexate to treat chronic gout

July 8, 2022

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2022/07/Comirnaty-Receives-Full-FDA-Approval-for-Expanded-Age-Group-480x360.jpg" class="scale-with-grid wp-post-image" alt="Comirnaty Receives Full FDA Approval for Expanded Age Group" decoding="async" />

Comirnaty Receives Full FDA Approval for Expanded Age Group

Comirnaty Receives Full FDA Approval for Expanded Age Group

July 8, 2022 – Comirnaty^® (COVID-19 vaccine, mRNA – Pfizer and BioNTech) is now FDA approved for use in adolescents who are 12-15 years old. This age group

July 6, 2022

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2022/07/Mylan-Recalls-One-Lot-of-Insulin-Glargine-480x360.jpg" class="scale-with-grid wp-post-image" alt="Mylan Recalls One Lot of Insulin Glargine" decoding="async" />

Mylan Recalls One Lot of Insulin Glargine

Mylan Recalls One Lot of Insulin Glargine

July 6, 2022 – Mylan Pharmaceuticals has recalled one batch of Insulin Glargine (insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3mL prefilled pens. The product

July 6, 2022

Pharmacists Now Able to Prescribe Paxlovid

July 6, 2022 – The U.S. FDA has revised emergency use authorization (EAU) for Pfizer’s Paxlovid^TM (nirmatrelvir and ritonavir) to allow state-licensed pharmacists